68Ga-CXCR4-targeted PET/CT Outperforms 18F-FDG PET/CT in FLT3-mutated AML M1 With Granulocytic Sarcoma: Theranostic Insights

68Ga-CXCR4靶向PET/CT在FLT3突变型伴粒细胞肉瘤的AML M1期患者中优于18F-FDG PET/CT:治疗诊断学见解

阅读:1

Abstract

68Ga-CXCR4 PET/CT was performed in a patient with acute myeloid leukemia (AML) and granulocytic sarcoma in the left cervical region, who had previously undergone 18F-FDG PET/CT. Compared with 18F-FDG PET/CT, 68Ga-CXCR4 PET/CT revealed a greater number of malignant lymph nodes with more intense uptake in both supradiaphragmatic and infradiaphragmatic regions. Furthermore, markedly increased radiotracer uptake was observed in the bone marrow and spleen compared with FDG. This case underscores the superior sensitivity of 68Ga-CXCR4 PET/CT in detecting AML infiltration and supports further investigation of CXCR4-targeted imaging and therapeutic approaches in high-risk AML.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。